Co-founder at Airbyte.io, the new standard for open-source data integration
For the context, Airbyte is an open-source data integration platform. Our goal is to commoditize data integration. In January, we shared how we were thinking about OKRs, along with our OKRs for Q1 2021. So we wanted to give some updates about them, and how they have evolved for the 2nd quarter.
Our focus for 2021 is to become the open-source standard for replicating data. This entails three overarching goals:
- Making Airbyte just work whatever your data infrastructure, volume and connector needs.
- Building the largest developer community for data integration. We envision that most connectors will be built and maintained by the community eventually, because we will have made that so simple with our low-code framework.
- Making Airbyte so easy to use in a production context that Airbyte becomes the new standard for data teams to replicate data.
Let’s see how this translates itself into our first two quarterly OKRs.
How We Performed on Airbyte’s OKRs for Q1 2021
1. O: Growing Community Love
What is community love? We’re still big fans of Orbit’s definition for it. Love is a member’s level of engagement and investment in the community. Someone with high love is highly active and plays key roles in the community, like contributing, moderating, and organizing.
Let’s first look at GitHub Stars
In this chart, we’re comparing Airbyte with other famous open-source projects around data integration: DBT and RudderStack. Our growth rate (Airbyte in red) is a huge validation that we’re not the only ones to believe that data integration will be solved with an open-source and community approach.
GitHub stars are good awareness metrics, but they don’t mean that you actually have community adoption or contribution. We need to look at other metrics for that:
Overall, we outperformed our Q1 OKRs for community love, even though we set aggressive goals. This is still the very beginning of our journey, but this was extremely encouraging for all the team. We strongly believe we can commoditize data integration through our growing community.
2. O: Growing Production Usage
We call “activated users” users who have deployed Airbyte, connected a source, a destination and synced data successfully from this source to this destination.
We call “prod users“ users who have been syncing data more than 5 times in the past week and 5 times in the week before.
Here’s a chart showing the evolution of activated users and prod users during Q1.
We don’t publish the number of prod users we have yet, but you can see that the conversion from activated to prod users is growing with time, which is what we want to see.
But, is the usage of Airbyte growing among prod users?
If we had to follow only one graph, it would be this one. It accounts for both prod user growth and usage growth within prod users.
Here’s the usage growth in terms of sync per prod user:
Overall, this was exactly what we wanted to see. Teams start by testing Airbyte for a few days or weeks, before expanding their usage to other connectors.
3. O: Becoming a Reliable Standard
Airbyte can only become the new standard if connectors are reliable. You could consider that a “sanity” metric — in the sense it is not related to some growth metrics -, but it is actually where almost all of the engineering work goes. The more users use Airbyte, the more edge cases connectors get exposed to. It is a thousand-paper-cut problem, where every user comes with their needs in terms of usage, data and volume. The more users we have, the less reliable connectors can appear, and we have to seize these opportunities to strengthen them.
The metrics we’re looking at in this case are the percent of failures at sync attempts:
We launched on HackerNews on January 26th. That’s when we gained a lot more users at once and got exposed to a lot more use cases. During the whole month of February, we worked on strengthening our connectors, and you can see in this chart how it paid off. Our KR was 5% of failures by the end of the quarter, and this is something that we will keep working on.
Some other metrics we wanted to track:
- KR: Response time to any message on Slack or GitHub — our goal was to reach 30 min by end of Q1 2021.
- KR: Time to high bug resolution — our goal is to reach 1.5 days by the end of Q1 2021.
In the end, we couldn’t really measure those 2 metrics. But the overall response time to any message on Slack was about 1–2 hours.
4. O: Building the Dream Team
We strongly believe in talent density, and that it’s better to have one stellar colleague than 5 average ones.
- KR: 2 A+ engineers => 3 engineers will be joining us in the next few weeks.
- KR: 1 senior developer advocate => Abhi will be joining us soon!
Our Q1 Milestones
Now that we have seen how we performed on our OKRs, how did we perform on the milestones?
- Hard launch on HackerNews
- Building tutorials to improve the developer experience (DX) in building their own connectors, or editing pre-built ones => this is still a work in progress.
Product engineering efforts
One thing we didn’t anticipate is the toll providing great support would take on our engineering velocity. Even though we had great output, we were not able to deliver on all the milestones we had intended.
For our core platform:
- Integration in data stack with DBT and Airflow => delivered, although we still have a lot on DBT’s front!
- Core upgrade strategy => delivered!
For our connectors:
- Strengthen our connectors so all our connectors are A+ => we started certifying our connectors against a set of best practice, and you can now see the health status of our connectors.
- Schemas migration management => reprioritized
- Seamless OAuth support => reprioritized
- More high-level abstractions to build connectors more easily => ongoing effort!
- An MVP for CDC (Capture Data Change) => delivered!
- Connector upgrade strategy => delivered!
- A public dashboard showing the stability (failure rate) of all our connectors => delivered!
Our New Q2 OKRs
So what about the next quarter? Doing OKRs is actually a great learning opportunity enabling us to make better estimates every time. This time, we have experience on how much time providing a great support experience takes in engineering time. So we can plan accordingly.
For Q2, we kept the same objectives but changed some KRs that we’ve put in bold.
O: Growing Community Love
- KR: Active Slack users (Q1/21: 350, Q2/21: 600)
- KR: GitHub stars (Q1/21: 2k, Q2/21: 4k)
- KR: Issue contributors from start (Q1/21: 125, Q2/21: 250)
- KR: PR contributors from start (Q1/21: 25, Q2/21: 50)
- KR: Connector Contributors (Q1/21: 10, Q2/21: 30)
O: Growing Prod Usage
- KR: Prod users
- KR: Active connections per prod user
- KR: # connectors (Q1/21: 56, Q2/21: 90)
O: Becoming a Reliable Standard
- KR: % failure at attempts
- KR: average throughput of connectors
- KR: support replicating large databases in X minutes
O: Building the Dream Team
- KR: 2 A+ engineers
- KR: 1 dev evangelist (to be confirmed) + 1 operations manager
Our Next Q2 Milestones
How does this translate into milestones?
- Make Airbyte the easiest way to create line-of-business connectors with our low-code solution for creating connectors quickly and more reliably.
- Support custom DBT models.CDC for all major database sources.
- Mature handling of (large) production data sets.
- Production-grade single node support (across platforms): creating solid AMIs, systemctl, etc., with less setup.
- First-class support on K8s.
- OAuth support for connector authentication.
- “Automatic” Schema change handling.
- Support for data lake use cases.
So…a lot of engineering milestones! And they can be accomplished as we grow our engineering team.
Let’s see how we perform in 3 months!
Previously published at https://airbyte.io/articles/our-story/how-we-performed-on-our-q1-okrs-and-the-goals-for-q2/
Create your free account to unlock your custom reading experience.
No lasting benefit to tubes over antibiotics for childhood ear infections
PITTSBURGH, May 12, 2021 – There is no long-term benefit to surgically placing tympanostomy tubes in a young child’s ears to reduce the rate of recurrent ear infections during the ensuing two years compared with giving oral antibiotics to treat ear infections, a randomized trial led by UPMC Children’s Hospital of Pittsburgh and University of Pittsburgh pediatrician-scientists determined.
The trial results, published today in the New England Journal of Medicine, are among the first since the pneumococcal vaccine was added to pediatric vaccination schedules, providing updated evidence that may help shape pediatric guidelines on treating recurrent ear infections. Importantly, despite their greater use of antibiotics, the trial found no evidence of increased bacterial resistance among children in the medical-management group.
“Subjecting a young child to the risks of anesthesia and surgery, the possible development of structural changes of the tympanic membrane, blockage of the tube or persistent drainage through the tube for recurrent ear infections, which ordinarily occur less frequently as the child ages, is not something I would recommend in most instances,” said lead author Alejandro Hoberman, M.D., director of the Division of General Academic Pediatrics at UPMC Children’s Hospital and the Jack L. Paradise Endowed Professor of Pediatric Research at Pitt’s School of Medicine.
“We used to often recommend tubes to reduce the rate of ear infections, but in our study, episodic antibiotic treatment worked just as well for most children,” he said. “Another theoretical reason to resort to tubes is to use topical ear drops rather than systemic oral antibiotics in subsequent infections in the hope of preventing the development of bacterial resistance, but in this trial, we did not find increased resistance with oral antibiotic use. So, for most children with recurrent ear infections, why undergo the risks, cost and nuisance of surgery?”
Next to the common cold, ear infections are the most frequently diagnosed illness in U.S. children. Ear infections can be painful, force lost time at work and school, and may cause hearing loss. Tympanostomy tube placement, which is a surgical procedure to insert tiny tubes into a child’s eardrums to prevent the accumulation of fluid, is the most common operation performed on children after the newborn period.
Hoberman and his team enrolled 250 children ages 6 to 35 months of age at UPMC Children’s Hospital, Children’s National Medical Center in Washington, D.C., and Kentucky Pediatric and Adult Research in Bardstown, Ky. All of the children had had medically verified recurrent ear infections and had received the pneumococcal conjugate vaccine. They were randomly assigned to receive “medical management,” which involved receiving oral antibiotics at the time of ear infections, or the surgical insertion of tubes and antibiotic ear drops. The children were followed for two years.
Overall, there were no differences between children in the two groups when it came to the rate or severity of ear infections. And, though the children in the medical management group received more antibiotics, there also was no evidence of increased antimicrobial resistance in samples taken from the children. The trial also didn’t find any difference between the two groups in the children’s quality of life or in the effect of the children’s illness on parents’ quality of life.
One short-term benefit of placing tympanostomy tubes was that, on average, it took about two months longer for a child to develop a first ear infection after tubes were placed, compared with children whose ear infections were managed with antibiotics.
Another finding of the trial was that the rate of ear infections among children in both groups fell with increasing age. The rate of infections was 2.6 times higher in children younger than 1 year, compared with the oldest children in the trial, those between 2 and 3 years, regardless of whether they received medical management or tube insertion.
“Most children outgrow ear infections as the Eustachian tube, which connects the middle-ear with the back of the throat, works better,” Hoberman said. “Previous studies of tubes were conducted before children were universally immunized with pneumococcal conjugate vaccine, which also has reduced the likelihood of recurrent ear infections. It’s important to recognize that most children outgrow ear infections as they grow older. However, we must appreciate that for the relatively few children who continue to meet criteria for recurrent ear infections–three in six months or four in one year–after having met those criteria initially, placement of tympanostomy tubes may well be beneficial.”
Additional study authors are Diego Preciado, M.D., Ph.D., and Daniel E. Felton, M.D., both of Children’s National Medical Center; Jack L. Paradise, M.D., David H. Chi, M.D., MaryAnn Haralam, M.S.N., C.R.N.P., Diana H. Kearney, R.N., C.C.R.C., Sonika Bhatnagar, M.D., M.P.H., Gysella B. Muñiz Pujalt, M.D., Timothy R. Shope, M.D., M.P.H., Judith M. Martin, M.D., Marcia Kurs-Lasky, M.S., Hui Liu, M.S., Kristin Yahner, M.S., Jong-Hyeon Jeong, Ph.D., Jennifer P. Nagg, R.N., Joseph E. Dohar, M.D., and Nader Shaikh, M.D., M.P.H., all of Pitt; Norman L. Cohen, M.D., and Brian Czervionke, M.D., both of UPMC Children’s Community Pediatrics; and Stan L. Block, M.D., of Kentucky Pediatric and Adult Research.
This research was funded by National Institute on Deafness and Other Communication Disorders grant NCT02567825.
To read this release online or share it, visit http://www.
About the University of Pittsburgh School of Medicine
As one of the nation’s leading academic centers for biomedical research, the University of Pittsburgh School of Medicine integrates advanced technology with basic science across a broad range of disciplines in a continuous quest to harness the power of new knowledge and improve the human condition. Driven mainly by the School of Medicine and its affiliates, Pitt has ranked among the top 10 recipients of funding from the National Institutes of Health since 1998. In rankings recently released by the National Science Foundation, Pitt ranked fifth among all American universities in total federal science and engineering research and development support.
Likewise, the School of Medicine is equally committed to advancing the quality and strength of its medical and graduate education programs, for which it is recognized as an innovative leader, and to training highly skilled, compassionate clinicians and creative scientists well-equipped to engage in world-class research. The School of Medicine is the academic partner of UPMC, which has collaborated with the University to raise the standard of medical excellence in Pittsburgh and to position health care as a driving force behind the region’s economy. For more information about the School of Medicine, see http://www.
About UPMC Children’s Hospital of Pittsburgh
Regionally, nationally, and globally, UPMC Children’s Hospital of Pittsburgh is a leader in the treatment of childhood conditions and diseases, a pioneer in the development of new and improved therapies, and a top educator of the next generation of pediatricians and pediatric subspecialists. With generous community support, UPMC Children’s Hospital has fulfilled this mission since its founding in 1890. UPMC Children’s is recognized consistently for its clinical, research, educational, and advocacy-related accomplishments, including ranking in the top 10 on the 2020-2021 U.S. News & World Report Honor Roll of America’s Best Children’s Hospitals. UPMC Children’s also ranks 15th among children’s hospitals and schools of medicine in funding for pediatric research provided by the National Institutes of Health (FY2019).
Contact: Allison Hydzik
E-mail: [email protected]
Contact: Andrea Kunicky
E-mail: [email protected]
Research reveals ancient people had more diverse gut microorganisms
MISSOULA – Only an anthropologist would treasure millennia-old human feces found in dry caves.
Just ask Dr. Meradeth Snow, a University of Montana researcher and co-chair of UM’s Department of Anthropology. She is part of an international team, led by the Harvard Medical School-affiliated Joslin Diabetes Center, that used human “paleofeces” to discover that ancient people had far different microorganisms living in their guts than we do in modern times.
Snow said studying the gut microbes found in the ancient fecal material may offer clues to combat diseases like diabetes that afflict people living in today’s industrialized societies.
“We need to have some specific microorganisms in the right ratios for our bodies to operate effectively,” Snow said. “It’s a symbiotic relationship. But when we study people today – anywhere on the planet – we know that their gut microbiomes have been influenced by our modern world, either through diet, chemicals, antibiotics or a host of other things. So understanding what the gut microbiome looked like before industrialization happened helps us understand what’s different in today’s guts.”
This new research was published May 12 in the prestigious journal Nature. The article is titled “Reconstruction of ancient microbial genomes from the human gut.” Snow and UM graduate student Tre Blohm are among the 28 authors of the piece, who hail from institutions around the globe.
Snow said the feces they studied came from dry caves in Utah and northern Mexico. So what does the 1,000-year-old human excrement look like?
“The caves these paleofeces came from are known for their amazing preservation,” she said. “Things that would normally degrade over time look almost brand new. So the paleofeces looked like, well, feces that are very dried out.”
Snow and Blohm worked hands-on with the precious specimens, suiting up in a clean-room laboratory at UM to avoid contamination from the environment or any other microorganisms – not an easy task when the tiny creatures are literally in and on everything. They would carefully collect a small portion that allowed them to separate out the DNA from the rest of the material. Blohm then used the sequenced DNA to confirm the paleofeces came from ancient people.
The senior author of the Nature paper is Aleksandar Kostic of the Joslin Diabetes Center. In previous studies of children living in Finland and Russia, he and his partners revealed that kids living in industrialized areas – who are much more likely to develop Type 1 diabetes than those in non-industrialized areas – have very different gut microbiomes.
“We were able to identify specific microbes and microbial products that we believe hampered a proper immune education in early life,” Kostic said. “And this leads later on to higher incidents of not just Type 1 diabetes, but other autoimmune and allergic diseases.”
Kostic wanted to find a healthy human microbiome without the effects of modern industrialization, but he became convinced that couldn’t happen with any modern living people, pointing out that even tribes in the remote Amazon are contracting COVID-19.
So that’s when the researchers turned to samples collected from arid environments in the North American Southwest. The DNA from eight well-preserved ancient gut samples were compared with the DNA of 789 modern samples. Half the modern samples came from people eating diets where most food comes from grocery stores, and the remainder came from people consuming non-industrialized foods mostly grown in their own communities.
The differences between microbiome populations were striking. For instance, a bacterium known as Treponema succinifaciens wasn’t in a single “industrialized” population’s microbiome the team analyzed, but it was in every single one of the eight ancient microbiomes. But researchers found the ancient microbiomes did match up more closely with modern non-industrialized population’s microbiomes.
The scientists found that almost 40% of the ancient microbial species had never been seen before. Kostic speculated on what caused the high genetic variability:
“In ancient cultures, the foods you’re eating are very diverse and can support a more eclectic collection of microbes,” Kostic said. “But as you move toward industrialization and more of a grocery-store diet, you lose a lot of nutrients that help to support a more diverse microbiome.”
Moreover, the ancient microbial populations incorporated fewer genes related to antibiotic resistance. The ancient samples also featured lower numbers of genes that produce proteins that degrade the intestinal mucus layer, which then can produce inflammation that is linked with various diseases.
Snow and several coauthors and museum collection managers also led a project to ensure the inclusion of Indigenous perspectives in the research.
“This was a really vital part of the work that had to accompany this kind of research,” she said. “Initially, we sent out multiple letters and emails and called the tribal historic preservation officers of the all the recognized tribes in the Southwest region. Then we met with anyone who was interested, doing short presentations and answering questions and following up with interested parties.
“The feedback we received was noteworthy, in that we needed to keep in mind that these paleofeces have to ties their ancestors, and we needed to be – and hopefully have been – as respectful as possible about them,” she said.
“There is a long history of misuse of genetic data from Indigenous communities, and we strove to be mindful of this by meeting and speaking with as many people as possible to obtain their insights and perspectives. We hope that this will set a precedent for us as scientists and others working with genetic material from Indigenous communities past and present.”
Snow said the research overall revealed some fascinating things.
“The biggest finding is that the gut microbiome in the past was far more diverse than today – and this loss of diversity is something we are seeing in humans around the world,” she said. “It’s really important that we learn more about these little microorganisms and what they do for us in our symbiotic relationships.
“In the end, it could make us all healthier.”
C-Path announces accelerated data sharing collaboration with Tufts Medical Center
FDA grant supports use of real-world data to generate real-world evidence in neonates
TUCSON, Ariz., May 12, 2021 — Critical Path Institute (C-Path) and Tufts Medical Center have announced a joint venture to integrate the first patient-level clinical trial data to generate actionable real-world evidence (RWE) for neonatal drug development, from real-world neonate data (RWD). This activity, funded by a grant from the U.S. Food and Drug Administration (FDA), is being executed through a neonatal pilot project within C-Path’s International Neonatal Consortium (INC). The data sharing collaboration and transfer also marks the fastest on record for C-Path — starting with the Data Contribution Agreement negotiations and receipt of the data in three months’ time this March.
“I’m extremely proud of both team’s efforts to move swiftly to integrate data, increase our understanding of neonates and improve drug development for this underserved population,” said INC Executive Director Kanwaljit Singh, M.D., M.P.H. “Dr. Jonathan Davis was key in this collaboration and we thank him for all he’s done to move this project forward quickly.”
This effort allows a unique set of clinical trial data to be integrated and managed by C-Path’s Data Collaboration Center (DCC) to support analyses run by its Quantitative Medicine Program. “This will significantly add to the goal of defining actionable reference ranges of commonly used laboratory values in neonates and the development of a natural history model of bronchopulmonary dysplasia,” indicated C-Path’s Chief Science Officer and project Co-Principal Investigator Klaus Romero, M.D., M.S., F.C.P.
The clinical trial data sets shared by Tufts MC will be integrated with other patient-level RWD from electronic health records and data from national registries and networks. Each year in the U.S., 10 percent of neonates are born preterm, creating an urgent need to improve survival and outcome. However, there is minimal new drug development and most existing drugs have insufficient evidence to support safety, efficacy and dosage in this high-risk population.
“I am privileged to work with this exceptional team of clinical and data scientists at C-Path that will make real advances in neonatology,” said Jonathan Davis, M.D., Chief of Newborn Medicine, Associate Director of the Tufts Clinical and Translational Science Institute at Tufts Children’s Hospital, and Co-Principal Investigator. “This collaboration is a perfect marriage. A balance between clinical care, clinical trials, and data science that has never been done before in the neonatology space.”
For more than 15 years, C-Path has engaged in numerous successful partnerships with the FDA and industry to act as a catalyst for drug development. The public-private partnership with FDA, industry, the academic community and families of preterm neonates is unprecedented. The overall goal is to collect, aggregate, standardize and analyze RWD and generate RWE to accelerate drug development efforts. “This style of partnership holds great promise to benefit the unmet needs of the neonatal population and will likely be generalizable to other populations and therapeutic areas as well,” said Singh.
C-Path’s DCC will develop the Real-World Data and Analytics Platform (RW-DAP) as an integrated database and analytics hub designed to be used in generating actionable RWE that can be leveraged to inform drug development in areas where RWD can play a relevant role. It will promote the sharing of relevant RWD and facilitate the optimization of future RWD collection. By integrating relevant RWD in a format suitable for analytics, the RW-DAP will accelerate the understanding of disease progression (including causes for variance in disease progression), clinical outcome measures and biomarkers, and facilitate the development of mathematical models of disease and innovative clinical trial designs. RW-DAP will be positioned to generate solutions to drug development, which can be made publicly available to qualified researchers in industry, government, regulatory agencies and academia.
“C-Path’s INC is well-equipped to lead this project. Real-world data and real-world evidence are crucial to understanding how medical product is performing, and more importantly, how we can make adjustments and explore its potential benefits for other therapeutic areas,” Romero said. “The development of the RW-DAP fits right within DCC’s impressive body of work.”
C-Path’s INC will continue to meet and work with collaborators and new data contributors to integrate additional patient-level datasets. For more information on collaborating with INC, and how to contribute data, please email Adriana Burns at [email protected]
Critical Path Institute is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) and is 55% funded by FDA/HHS, totaling $14,575,306, and 45% funded by non-government source(s), totaling $11,916,747. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government. For more information, please visit FDA.gov.
Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and dozens of pharmaceutical and biotech companies. C-Path U.S. is headquartered in Tucson, Arizona and C-Path, Ltd. EU is headquartered in Dublin, Ireland, with additional staff in multiple other locations. For more information, visit c-path.org and c-path.eu.
Previously unknown letter reveals Einstein’s thinking on bees, birds and physics
A recently discovered letter written by Albert Einstein discusses a link between physics and biology, seven decades before evidence emerges.
Credit: Dyer et al. 2021, J Comp Physiol A / The Hebrew University of Jerusalem
The 1949 letter by the physicist and Nobel laureate discusses bees, birds and whether new physics principles could come from studying animal senses.
It’s a position still being realised within physics to this day, with a growing body of research and understanding of how animals such as birds and bees find their way around.
Now a study led by RMIT University in Melbourne, Australia, discusses how recent discoveries in migratory birds back up Einstein’s thinking 72 years ago.
The previously unpublished letter was shared with researchers by Judith Davys – Einstein had addressed it to her late husband, radar researcher Glyn Davys.
RMIT’s Associate Professor Adrian Dyer has published significant studies into bees and is the lead author of the new paper on Einstein’s letter, published in the Journal of Comparative Physiology A.
Dyer said the letter shows how Einstein envisaged new discoveries could come from studying animals.
“Seven decades after Einstein proposed new physics might come from animal sensory perception, we’re seeing discoveries that push our understanding about navigation and the fundamental principles of physics,” he said.
The letter also proves Einstein met with Nobel laurate Karl von Frisch, who was a leading bee and animal sensory researcher.
In April 1949, von Frisch presented his research on how honeybees navigate more effectively using the polarisation patterns of light scattered from the sky.
The day after Einstein attended von Frisch’s lecture, the two researchers shared a private meeting.
Although this meeting wasn’t formally documented, the recently discovered letter from Einstein provides insight into what they might have talked about.
“It is thinkable that the investigation of the behaviour of migratory birds and carrier pigeons may someday lead to the understanding of some physical process which is not yet known,” Einstein wrote.
Professor Andrew Greentree, a theoretical physicist at RMIT, said Einstein also suggested that for bees to extend our knowledge of physics, new types of behaviour would need to be observed.
“Remarkably, it is clear through his writing that Einstein envisaged new discoveries could come from studying animals’ behaviours,” Greentree said.
More than 70 years since Einstein sent his letter, research is revealing the secrets of how migratory birds navigate while flying thousands of kilometres to arrive at a precise destination.
In 2008, research on thrushes fitted with radio transmitters showed, for the first time, that these birds use a form of magnetic compass as their primary orientation guide during flight.
One theory for the origin of magnetic sense in birds is the use of quantum randomness and entanglement. Both of these physics concepts were first proposed by Einstein.
The letter to Glyn Davys shows the openness of Einstein’s mind to novel possibilities observed in nature and the evidence that he took an interest in von Frish and his bee research.
‘Einstein, von Frisch and the honeybee: a historical letter comes to light’, with Adrian Dyer, Andrew Greentree, Jair Garcia, Elinya Dyer, Scarlett Howard and Fredrich Barth, is published in the Journal of Comparative Physiology A (DOI: 10.1007/s00359-021-01490-6).
What Happened To Lufthansa’s Boeing 707 Aircraft?
Launch of Crypto Trading Team by Goldman Sachs
JetBlue Hits Back At Eastern Airlines On Ecuador Flights
Cybersecurity Degrees in Massachusetts — Your Guide to Choosing a School
United Airlines Uses The Crisis To Diversify Latin American Network
Miten tekoälyä käytetään videopeleissä ja mitä tulevaisuudessa on odotettavissa
DOGE Co-founder Reveals the Reasons Behind its Price Rise
“Privacy is a ‘Privilege’ that Users Ought to Cherish”: Elena Nadoliksi
U.S. and the U.K. Published Attack on IT Management Company SolarWinds
Build a cognitive search and a health knowledge graph using AWS AI services
The Spanish fintech Pecunpay strengthens its position as a leader in the issuance of corporate programs
This Dream Job Will Pay You to Gamble in Las Vegas on the Company’s Dime
Nasdaq-Listed Metromile Backs Bitcoin for its Insurance Products
Crypto.com Now Enabling Cosmos’ Inter-Blockchain Communication Functionality for Cross-Chain Transfers
Cybersecurity Degrees in Texas — Your Guide to Choosing a School
What We Know About Tesla’s “Bobcat Project”
ONE Gas to Participate in American Gas Association Financial Forum
Meme Coins Craze Attracting Money Behind Fall of Bitcoin
Ryanair Goes Full Steam Ahead On Portugal Capacity Expansion
PR Newswire6 days ago
Polystyrene Foam Market worth $32.2 billion by 2026 – Exclusive Report by MarketsandMarkets™
Blockchain1 week ago
Munger ‘Anti-Bitcoin’ and Buffett ‘Annoyance’ Towards Crypto Industry
Blockchain1 week ago
Ethereum hits $3,000 for the first time, now larger than Bank of America
Blockchain1 week ago
The Reason for Ethereum’s Recent Rally to ATH According to Changpeng Zhao
Energy1 week ago
Systém GameChange Solar 631 MW Genius Tracker™ bude vztyčen v jižním Texasu
SPACS1 week ago
Deutsche Boerse expects 12 SPACs in Frankfurt in 2021
Aviation1 week ago
American Airlines Passenger Arrested After Alleged Crew Attack
Blockchain7 days ago
Chiliz Price Prediction 2021-2025: $1.76 By the End of 2025
Business Insider1 week ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BELLUS Health Inc. – BLU
Blockchain1 week ago
Mining Bitcoin: How to Mine Bitcoin
Blockchain1 week ago
Ethereum Market Capital Overtakes Bank of America
Blockchain1 week ago
Bitcoin Gains Bullish Momentum, Signals Another Major Rally